Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Polyneuropathies
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT number NCT06290141
Study type Interventional
Source Sanofi
Contact Trial Transparency email recommended (Toll free for US & Canada)
Phone 800-633-1610
Email Contact-US@sanofi.com
Status Recruiting
Phase Phase 3
Start date May 31, 2024
Completion date May 19, 2027

See also
  Status Clinical Trial Phase
Completed NCT02465359 - Subcutaneous Immunoglobulin for CIDP N/A
Recruiting NCT05584631 - IVIG vs SCIG in CIDP Phase 1
Withdrawn NCT01236456 - High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Terminated NCT03779828 - Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Completed NCT01184846 - Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Phase 3
Recruiting NCT05011006 - NT-3 Levels and Function in Individuals With CMT
Completed NCT01379833 - Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Completed NCT02414490 - IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Completed NCT01545076 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Phase 3
Active, not recruiting NCT00716066 - Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Phase 2
Recruiting NCT04672733 - Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Not yet recruiting NCT04480450 - Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Not yet recruiting NCT05219383 - Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
Completed NCT02111590 - Immunoglobulin Dosage and Administration Form in CIDP and MMN N/A
Recruiting NCT04292834 - A Registered Cohort Study of Immune-Mediated Neuropathies
Terminated NCT03772717 - Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) N/A
Completed NCT00278629 - Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Recruiting NCT02372149 - IVIg for Demyelination in Diabetes Mellitus Phase 4
Completed NCT00962429 - Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Phase 2